ChugaiCHUGAI PHARMACEUTICAL CO., LTD.4519東証プライム医薬品FY ending Dec 2023, consolidated, IFRS

Chugai FY ending Dec 2022 results

Chugai brought in ¥1.26T in revenue.

Revenue changed +26.0% from the prior year.

What changed from last year

FY ending Dec 2021 → FY ending Dec 2022

FY ending Dec 2021 → FY ending Dec 2022

※ Cost of revenue is not disclosed; expenses are combined

※ Operating income is not disclosed; the chart goes straight to pretax income including investment gains

A machine-readable operating income value exists, but it is not in the validated published data, so the chart is omitted.

Show source documents (6)

EDINET (FSA Japan)
有価証券報告書－第115期(2025/01/01－2025/12/31)
ID S100XTBJ2026-03-25Open
EDINET (FSA Japan)
有価証券報告書－第114期(2024/01/01－2024/12/31)
ID S100VHBT2025-03-27Open
EDINET (FSA Japan)
訂正有価証券報告書－第113期(2023/01/01－2023/12/31)
ID S100U3VS2024-07-26Open
EDINET (FSA Japan)
有価証券報告書－第112期(2022/01/01－2022/12/31)
ID S100QH692023-03-30Open
EDINET (FSA Japan)
訂正有価証券報告書－第111期(令和3年1月1日－令和3年12月31日)
ID S100NSNY2022-03-30Open
EDINET (FSA Japan)
有価証券報告書－第110期(令和2年1月1日－令和2年12月31日)
ID S100KZU52021-03-23Open

Extracted from XBRL: 10 / Derived from other figures: 1

Spotted an error? Report it (corrections keep the original record)

Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.